Passik Steven D, Kirsh Kenneth L, Twillman Robert K
Millennium Research Institute, San Diego,California; Vice President, Clinical Research and Advocacy, Millennium Health, San Diego, California.
Millennium Research Institute, San Diego, California; Vice President, Clinical Research and Advocacy, Millennium Health, San Diego, California.
J Opioid Manag. 2015 Jan-Feb;11(1):77-81. doi: 10.5055/jom.2015.0255.
Both prescription drug monitoring programs (PDMP) and urine drug testing (UDT) are recommended as parts of an ongoing risk management approach for controlled substance prescribing. The authors provide an editorial and commentary to discuss the unique contributions of each to promote better clinical decision making for prescribers.
A commentary is employed along with brief discussion comparing four states with an active PDMP in place to three states without an active PDMP as it relates back to findings on UDT in those states from a laboratory conducting liquid chromatography tandem mass spectrometry.
The commentary focuses on the place of both tools (UDT and PDMP) in risk management efforts. The argument is made that relying on a PDMP alone would lead to clinical decisions that may miss a great deal of problematic or aberrant behaviors.
处方药监测计划（PDMP）和尿液药物检测（UDT）均被推荐作为持续进行的受控物质处方风险管理方法的组成部分。作者发表一篇社论及评论，以讨论二者各自对促进开处方者做出更好临床决策的独特贡献。
采用一篇评论，并简要讨论了四个实施了活跃PDMP的州与三个未实施活跃PDMP的州，这与一家进行液相色谱串联质谱分析的实验室在这些州关于UDT的研究结果相关。
该评论聚焦于这两种工具（UDT和PDMP）在风险管理工作中的地位。文中指出，仅依靠PDMP会导致临床决策可能遗漏大量有问题或异常的行为。
